Brookfield Asset Management’s private equity arm and Caisse de dépôt et placement du Québec (CDPQ) are in advanced discussions to acquire Antylia Scientific from private equity firm GTCR, according to a report by Bloomberg citing sources familiar with the matter.
The deal, which could value the life sciences diagnostics provider at approximately $1.4bn, remains confidential, with representatives from Brookfield, CDPQ, and GTCR reportedly declining to comment.
Formerly known as Cole-Parmer, Antylia Scientific supplies biopharma, environmental, and life sciences companies, according to its website.
Healthcare remains a strong focus for private equity investors, driven by pharmaceutical companies’ pursuit of next-generation treatments and PE firms’ efforts to generate returns through strategic exits.
In a separate transaction, CVC Capital Partners is reportedly exploring options for its majority stake in French diagnostics firm Sebia, which could be valued at around €6bn ($6.5bn), according to Bloomberg.
The potential Antylia deal adds to Brookfield’s active start to 2025. In Q1 alone, its private equity group completed a $4.5bn dividend recapitalisation of Clarios International and acquired nVent Electric’s heating cables business for $1.7bn in cash.
Meanwhile, CDPQ, which manages approximately $330bn, continues to prioritise direct investments while increasingly leveraging third-party managers and strategic partnerships, CEO Charles Emond said in February.
